Trial Profile
A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Nov 2020 Results estimating the impact of omalizumab on paid and unpaid work presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 11 Dec 2019 According to a Novartis Pharmaceuticals media release, Novartis Receives Approval for Additional Application of Zolea the World's First Antibody for Seasonal Allergic Rhinitis based on results of this trial.
- 04 Oct 2019 Results presented in a Novartis Media Release.